---
document_datetime: 2025-07-30 15:02:55
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vyvgart-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vyvgart-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.9027028
conversion_datetime: 2025-12-28 19:03:25.230514
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vyvgart

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0020              | Extension of indication to include the monotherapy treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins for Vyvgart, based on final results from study ARGX-113-1802; | 25/04/2025                          | 19/06/2025                                  | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | this is a pivotal study to investigate the efficacy, safety and tolerability of efgartigimod PH20 SC in adult patients CIDP; and based on interim results from study ARGX-113-1902; this is an open-label extension study of the ARGX-113-1802 trial to investigate the long-term safety, tolerability and efficacy of efgartigimod PH20 SC in patients with CIDP. As a consequence, sections 4.1, 4.2. 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. RMP is updated to version 3.0 In addition, the MAH took the opportunity to implement editorial changes to the SmPC and to update the list of local representatives in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11014 /202406 | Periodic Safety Update EU Single assessment - efgartigimod alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/01/2025 | 28/03/2025 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11014/202406.                                                                                                                                                                                                                                                                                                                                                                   |
| II/0022/G           | This was an application for a group of variations. In view of the data submitted with the group of variations, amendments to Annex(es) I, II, IIIA, IIIB and A and to the Risk Management Plan are recommended. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 13/02/2025 | 19/06/2025 | SmPC, Annex II, Labelling and PL | The SmPC, labelling and package leaflet have been updated to reflect the introduction of a pre-filled syringe presentation of 5.0 ml (200 mg/ml) (1000 mg strength) Vyvgart solution for injection and the corresponding method of administration, changes in excipient composition as well as shelf life and storage conditions for the finished product (2 years when stored at 2-8°C and for a single period of up to 1 month at room temperature up to 30°C). The additional presentations are packs of: |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Replacement/addition control/testing takes B.I.z - Quality change variation B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.II.e.5.a.2 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently B.II.a.5 - Change in concentration total use parenteral product, AS per unit dose (i.e. the same B.II.b.1.c - Replacement manufacturing site for the manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.a.3.b.5 - Changes in (excipients) of the finished   | of a site where batch place - Active substance - Other   | - 1 pre-filled syringe (EU/1/22/1674/003) - 4 pre-filled syringes (EU/1/22/1674/004)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                                                                                                                                   |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0024/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 10/12/2024 | n/a |                                   |
| PSUSA/11014 /202312 | Periodic Safety Update EU Single assessment - efgartigimod alfa                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11/07/2024 | n/a | PRAC Recommendation - maintenance |
| II/0017             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                                                                                       | 27/06/2024 | n/a |                                   |
| IA/0021             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18/06/2024 | n/a |                                   |
| II/0016             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch                                                                                                                                                                                                                                                                                                                                                   | 30/05/2024 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                    |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0019             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                       | 08/05/2024 | n/a        |                        |                                   |
| II/0014             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                          | 11/04/2024 | 29/08/2024 | SmPC and PL            |                                   |
| PSUSA/11014 /202306 | Periodic Safety Update EU Single assessment - efgartigimod alfa                                                                                                                            | 11/01/2024 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0013             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                     | 08/01/2024 | n/a        |                        |                                   |
| IB/0015             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol        | 19/12/2023 | 29/08/2024 | SmPC and PL            |                                   |
| X/0003              | Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration | 14/09/2023 | 15/11/2023 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0012             | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 06/10/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006             | Update of sections 4.4 and 4.5 of the SmPC in order to amend an existing warning on use of vaccination and update drug-drug interaction information on vaccines based on final results from study ARGX- 113-2102; this is a phase 1, randomized, open-label, placebo-controlled, parallel-group study to evaluate the immune response to PNEUMOVAX 23 in healthy participants receiving efgartigimod IV 10 mg/kg or placebo. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 2.1 was adopted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 28/09/2023   | 29/08/2024 | SmPC and PL | Sections 4.4 and 4.5 of the SmPC are updated to inform that the safety of immunisation with live or live attenuated vaccines and the response to immunisation with these vaccines during treatment with efgartigimod alfa are unknown. For patients that are being treated with efgartigimod alfa, vaccination with live or live attenuated vaccines is generally not recommended. If vaccination with live or live attenuated vaccines is required, these vaccines should be administered at least 4 weeks before treatment and at least 2 weeks after the last dose of efgartigimod alfa. However, other vaccines may be administered as needed at any time during treatment with efgartigimod alfa. |
| PSUSA/11014 /202212 | Periodic Safety Update EU Single assessment - efgartigimod alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 20/07/2023   | 15/09/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11014/202212.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0010/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/08/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | limits of an AS, starting material/intermediate/reagent - Deletion of a non- specification parameter (e.g. deletion of obsolete parameter)                                                                                                                                                                                                                                                                 |            |     | and/or significant an                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------|
| IB/0009   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                        | 24/08/2023 | n/a |                                         |
|           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting                                                 | 30/06/2023 | n/a | IA/0008/G material/intermediate/reagent |
| IA/0007/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 30/06/2023 | n/a |                                         |

<div style=\"page-break-after: always\"></div>

|           | in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                     |            |            |             | B.I.b.1.d - Change   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------|
| II/0004/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 14/04/2023 | n/a        |             |                      |
| IB/0002/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/11/2022 | 15/09/2023 | SmPC and PL |                      |

<div style=\"page-break-after: always\"></div>

|        | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol   |            |            |    |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| N/0001 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                      | 22/09/2022 | 15/09/2023 | PL |